tirzepatide is fda approved vs. Semaglutide: What You Should Know Lilly's Zepbound (aka tirzepatide) Lands

Novo Nordisk, the company that developed it, walked away in the early 2000s and never filed for approval

Its solution-based configuration allows for direct integration into cell-free biochemical assays, receptor-ligand interaction models, and high-throughput mechanistic screening platforms without the need for complex reconstitution

Averaged out, this is roughly **1.4 kg per month** (or about 3.1 lbs per month)

Endocrinology The study The influence of 11-dehydro-17-hydroxycorticosterone (compound E) on the growth of malignant tumor in the mouse by Heilman and Kendall, published in 1944 in Endocrinology, explores the effects of a specific compound, 11-dehydro-17-hydroxycorticosterone (known as compound E), on the growth of malignant tumors in mice

PMID 14523363